Sudarshan Pharma Industries Ltd Falls 2.23%: 4 Key Factors Driving the Weekly Shift

4 May: Mildly Bullish Momentum Emerges Amid Sector Rally

On 4 May 2026, Sudarshan Pharma’s stock price closed at Rs.30.99, marking a subtle shift from a sideways trend to a mildly bullish technical stance. This change was supported by bullish daily moving averages and a weekly MACD indicator signalling improving medium-term momentum. Despite the monthly MACD remaining mildly bearish, the weekly Know Sure Thing (KST) indicator also suggested a positive near-term outlook. The stock’s 52-week range of Rs.18.50 to Rs.35.19 highlighted its volatility, yet the technical signals indicated potential for upward price movement within the specialty chemicals sector.

5 May: Bullish Momentum Strengthens with Technical Upgrades

The following day, Sudarshan Pharma’s price edged up slightly to Rs.31.00, a 0.03% increase from the previous close, supported by a bullish upgrade in technical momentum from mildly bullish to bullish. Key indicators such as the MACD on weekly charts and daily moving averages confirmed this positive shift. Bollinger Bands on the weekly timeframe showed the price trending near the upper band, signalling strong buying interest. However, monthly indicators remained neutral or mildly bearish, suggesting that while short-term momentum was robust, longer-term confirmation was pending.

6 May: Upgrade to Buy on Strong Financial and Technical Performance

MarketsMOJO upgraded Sudarshan Pharma’s rating from Hold to Buy on 6 May 2026, reflecting a marked improvement in financial and technical metrics. The company reported record quarterly results for the period ending March 2026, with net sales reaching Rs.220.92 crores and PBDIT surging to Rs.20.19 crores. Net profit after tax rose to Rs.10.73 crores, with earnings per share at Rs.0.45, the highest quarterly EPS recorded. Despite an increased interest expense of Rs.7.53 crores and a Debt to EBITDA ratio of 5.77 times, the company’s valuation metrics remained attractive, including a ROCE of 10.5% and a PEG ratio of 0.9.

Technically, the stock maintained a bullish stance with weekly MACD and Bollinger Bands supporting upward momentum, while monthly indicators suggested sideways consolidation. The stock price closed at Rs.30.99, marginally up from the previous day, continuing its recovery phase within the specialty chemicals sector.

7 May: Technical Momentum Moderates Amid Mixed Signals

On 7 May, Sudarshan Pharma’s stock price declined by 2.39% to close at Rs.30.01, reflecting a shift from bullish to mildly bullish technical momentum. Daily moving averages remained bullish, but the monthly MACD turned mildly bearish, signalling caution for longer-term investors. The weekly MACD and KST indicators stayed mildly bullish, while the Relative Strength Index (RSI) remained neutral across weekly and monthly timeframes.

Bollinger Bands presented a mixed picture, with weekly bands mildly bullish but monthly bands bearish, indicating potential volatility ahead. Dow Theory assessments echoed this uncertainty, showing no clear monthly trend. The stock’s Mojo Score improved to 71.0, upgrading its rating to Buy, highlighting enhanced confidence despite the recent price pullback.

8 May: Week Closes with Slight Recovery but Overall Decline

On the final trading day of the week, Sudarshan Pharma rebounded modestly, closing at Rs.30.30, up 0.97% from the previous day. Despite this recovery, the stock ended the week down 2.23% from its opening price of Rs.30.99, underperforming the Sensex which gained 1.25% over the same period. The stock’s volume fluctuated throughout the week, with notable spikes on 4 and 7 May, reflecting investor activity amid the technical and fundamental developments.

The mixed technical signals and recent upgrade to Buy suggest a cautiously optimistic outlook, with investors advised to monitor key support and resistance levels, including the 52-week high of Rs.35.19 and the low of Rs.18.50, to gauge the sustainability of momentum going forward.

Key Takeaways

Positive Signals: The upgrade to a Buy rating by MarketsMOJO on 6 May was driven by strong quarterly financials, including record net sales of Rs.220.92 crores and a net profit of Rs.10.73 crores. Technical indicators on weekly and daily charts showed bullish momentum, supported by moving averages and MACD signals. The stock’s long-term performance remains impressive, with a three-year return exceeding 330%, significantly outperforming the Sensex.

Cautionary Notes: Despite short-term strength, monthly technical indicators such as MACD and Bollinger Bands remain neutral to bearish, suggesting potential volatility and consolidation ahead. The company’s elevated Debt to EBITDA ratio of 5.77 times and increased interest expenses highlight financial risks that require monitoring. Additionally, the stock’s micro-cap status and lack of domestic mutual fund ownership may limit liquidity and institutional support.

Conclusion

Sudarshan Pharma Industries Ltd’s week was characterised by a complex interplay of technical momentum shifts and fundamental improvements. While the stock closed the week down 2.23%, it demonstrated resilience through a strong financial quarter and a significant upgrade to a Buy rating. The mixed technical signals, particularly on longer timeframes, counsel a measured approach for investors. The company’s robust long-term returns and improving fundamentals position it as a noteworthy player in the specialty chemicals sector, albeit with risks typical of micro-cap stocks. Monitoring key technical levels and financial metrics will be essential to assess the sustainability of the current momentum in the coming weeks.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →